Alternative splicing and related RNA binding proteins in human health and disease

Abstract

Alternative splicing (AS) serves as a pivotal mechanism in transcriptional regulation, engendering transcript diversity, and modifications in protein structure and functionality. Across varying tissues, developmental stages, or under specific conditions, AS gives rise to distinct splice isoforms. This implies that these isoforms possess unique temporal and spatial roles, thereby associating AS with standard biological activities and diseases. Among these, AS-related RNA-binding proteins (RBPs) play an instrumental role in regulating alternative splicing events. Under physiological conditions, the diversity of proteins mediated by AS influences the structure, function, interaction, and localization of proteins, thereby participating in the differentiation and development of an array of tissues and organs. Under pathological conditions, alterations in AS are linked with various diseases, particularly cancer. These changes can lead to modifications in gene splicing patterns, culminating in changes or loss of protein functionality. For instance, in cancer, abnormalities in AS and RBPs may result in aberrant expression of cancer-associated genes, thereby promoting the onset and progression of tumors. AS and RBPs are also associated with numerous neurodegenerative diseases and autoimmune diseases. Consequently, the study of AS across different tissues holds significant value. This review provides a detailed account of the recent advancements in the study of alternative splicing and AS-related RNA-binding proteins in tissue development and diseases, which aids in deepening the understanding of gene expression complexity and offers new insights and methodologies for precision medicine.

References 511

1. 1.

   Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell. 2019;76:329-345.

   Not in our library10.1016/j.molcel.2019.09.017

2. 2.

   Khan MR, Wellinger RJ, Laurent B. Exploring the alternative splicing of long noncoding RNAs. Trends Genet. 2021;37:695-698.

   Not in our library10.1016/j.tig.2021.03.010

3. 3.

   Rogers SO. Integrated evolution of ribosomal RNAs, introns, and intron nurseries. Genetica. 2019;147:103-119.

   Not in our library10.1007/s10709-018-0050-y

4. 4.

   Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat. Rev. Mol. Cell Biol. 2023;24:242-254.

   Not in our library10.1038/s41580-022-00545-z

5. 5.
   RNA modifications in brain tumorigenesis · 2020

   Not checked
6. 6.

   Hoyos LE, Abdel-Wahab O. Cancer-specific splicing changes and the potential for splicing-derived neoantigens. Cancer Cell. 2018;34:181-183.

   Not in our library10.1016/j.ccell.2018.07.008

7. 7.

   Wang S, Sun Z, Lei Z, Zhang HT. RNA-binding proteins and cancer metastasis. Semin. Cancer Biol. 2022;86:748-768.

   Not in our library10.1016/j.semcancer.2022.03.018

8. 8.

   Choi S, Cho N, Kim KK. The implications of alternative pre-mRNA splicing in cell signal transduction. Exp. Mol. Med. 2023;55:755-766.

   Not in our library10.1038/s12276-023-00981-7

9. 9.
   RNA-binding proteins in tumor progression · 2020

   No notice
10. 10.

    Swanson M, et al. Dynamic mutations and RNA mis-splicing in disease. Eur. J. Hum. Genet. 2019;27:1050-1050.

    Not in our library

11. 11.

    Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat. Rev. Genet. 2016;17:19-32.

    Not in our library10.1038/nrg.2015.3

12. 12.

    Saldi T, Riemondy K, Erickson B, Bentley DL. Alternative RNA structures formed during transcription depend on elongation rate and modify RNA processing. Mol. Cell. 2021;81:1789-1801.e1785.

    Not in our library10.1016/j.molcel.2021.01.040

13. 13.

    Wilkinson ME, Charenton C, Nagai K. RNA splicing by the spliceosome. Annu. Rev. Biochem. 2020;89:359-388.

    Not in our library10.1146/annurev-biochem-091719-064225

14. 14.
    A large-scale binding and functional map of human RNA-binding proteins · 2020

    Corrected
15. 15.

    Van Nostrand EL, et al. Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP). Nat. Methods. 2016;13:508-514.

    Not in our library10.1038/nmeth.3810

16. 16.

    Jankowsky E, Harris ME. Specificity and nonspecificity in RNA-protein interactions. Nat. Rev. Mol. Cell Biol. 2015;16:533-544.

    Not in our library10.1038/nrm4032

17. 17.

    Erkelenz S, et al. Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. Rna. 2013;19:96-102.

    Not in our library10.1261/rna.037044.112

18. 18.

    Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3:506-528.

    Not in our library10.1016/j.trecan.2017.05.003

19. 19.

    Fica SM, et al. RNA catalyses nuclear pre-mRNA splicing. Nature. 2013;503:229-234.

    Not in our library10.1038/nature12734

20. 20.

    Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701-718.

    Not in our library10.1016/j.cell.2009.02.009

21. 21.

    Ying Y, et al. Splicing activation by Rbfox requires self-aggregation through its tyrosine-rich domain. Cell. 2017;170:312-323.e310.

    Not in our library10.1016/j.cell.2017.06.022

22. 22.

    Padgett RA. New connections between splicing and human disease. Trends Genet. 2012;28:147-154.

    Not in our library10.1016/j.tig.2012.01.001

23. 23.

    Wright CJ, Smith CWJ, Jiggins CD. Alternative splicing as a source of phenotypic diversity. Nat. Rev. Genet. 2022;23:697-710.

    Not in our library10.1038/s41576-022-00514-4

24. 24.

    Wan R, Bai R, Zhan X, Shi Y. How is precursor messenger RNA spliced by the spliceosome? Annu. Rev. Biochem. 2020;89:333-358.

    Not in our library10.1146/annurev-biochem-013118-111024

25. 25.

    Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat. Rev. Mol. Cell Biol. 2017;18:18-30.

    Not in our library10.1038/nrm.2016.116

26. 26.

    Pal S, Gupta R, Davuluri RV. Alternative transcription and alternative splicing in cancer. Pharmacol. Ther. 2012;136:283-294.

    Not in our library10.1016/j.pharmthera.2012.08.005

27. 27.

    Urbanski LM, Leclair N, Anczukow O. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wires Rna. 2018;9:e1476.

    Not in our library10.1002/wrna.1476

28. 28.

    Liu MM, Zack DJ. Alternative splicing and retinal degeneration. Clin. Genet. 2013;84:142-149.

    Not in our library10.1111/cge.12181

29. 29.

    Matera AG, Wang ZF. A day in the life of the spliceosome (vol 15, pg 108, 2014). Nat. Rev. Mol. Cell Biol. 2014;15:108-121.

    Not in our library10.1038/nrm3742

30. 30.

    Zhou HL, Luo G, Wise JA, Lou H. Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res. 2014;42:701-713.

    Not in our library10.1093/nar/gkt875

31. 31.

    Do HTT, Shanak S, Barghash A, Helms V. Differential exon usage of developmental genes is associated with deregulated epigenetic marks. Sci. Rep. 2023;13:12256.

    Not in our library10.1038/s41598-023-38879-z

32. 32.

    El-Samad H. Biological feedback control—respect the loops. Cell Syst. 2021;12:477-487.

    Not in our library10.1016/j.cels.2021.05.004

33. 33.

    Pullmann R, et al. Analysis of turnover and translation regulatory RNA-binding protein expression through binding to cognate mRNAs. Mol. Cell Biol. 2007;27:6265-6278.

    Not in our library10.1128/mcb.00500-07

34. 34.

    Ding F, et al. Dynamics and functional roles of splicing factor autoregulation. Cell Rep. 2022;39:110985.

    Not in our library10.1016/j.celrep.2022.110985

35. 35.

    Zhou KI, et al. Regulation of co-transcriptional pre-mRNA splicing by m(6)A through the low-complexity protein hnRNPG. Mol. Cell. 2019;76:70-81.e79.

    Not in our library10.1016/j.molcel.2019.07.005

36. 36.

    Zhang X, et al. An atomic structure of the human spliceosome. Cell. 2017;169:918-929.e914.

    Not in our library10.1016/j.cell.2017.04.033

37. 37.

    Bertram K, et al. Cryo-EM structure of a pre-catalytic human spliceosome primed for activation. Cell. 2017;170:701-713.e711.

    Not in our library10.1016/j.cell.2017.07.011

38. 38.

    Venables JP, et al. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol. Cell Biol. 2013;33:396-405.

    Not in our library10.1128/mcb.01174-12

39. 39.

    Brosseau JP, et al. Tumor microenvironment-associated modifications of alternative splicing. Rna. 2014;20:189-201.

    Not in our library10.1261/rna.042168.113

40. 40.

    Lambert N, et al. RNA Bind-n-Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins. Mol. Cell. 2014;54:887-900.

    Not in our library10.1016/j.molcel.2014.04.016

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.